This single arm observational study will assess the duration and safety of treatment with trastuzumab in routine clinical practice in participants with early or metastatic HER2-positive breast cancer. Data will be collected from female participants treated with trastuzumab according to the Summary of Product Characteristics and local protocols. Duration of observation for each participant is from therapy initiation until permanent discontinuation for any cause.
Study Type
OBSERVATIONAL
Enrollment
250
Trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines
Cluj Clinical County Hospital; Oncology Dept
Cluj-Napoca, Romania
Treatment Duration With Trastuzumab in the Routine Clinical Practice
Time frame: Baseline up to 5 years
Percentage of Participants Who Discontinued Trastuzumab Therapy According to Reasons for Discontinuation
Time frame: Baseline up to 5 years
Percentage of Participants Who Received Previous Neoadjuvant Therapy
As a neoadjuvant therapy, participants received chemotherapy alone, radiotherapy alone, hormonal therapy alone or combination of these therapies. Percentage of participants who received these therapies is reported.
Time frame: Baseline up to 5 years
Percentage of Participants Who Had Surgical Procedure for Breast Cancer
Percentage of participants who underwent different types of surgical procedures for breast cancer are reported. Different types of surgical procedures included: breast-conserving surgery; mastectomy; and other (any other surgical procedure except breast-conserving surgery and mastectomy).
Time frame: Baseline up to 5 years
Percentage of Participants Who Received Trastuzumab as Adjuvant Therapy of HER2 Positive Breast Cancer
Time frame: Baseline up to 5 years
Progression Free Survival
Progression free survival was defined as the time from first dose of trastuzumab to disease progression as assessed by treating physician. Due to observational nature of the study, there was no specific method of assessment used to define progressive disease. Progressive disease was confirmed by treating physician, based on his/her assessment according to local practice.
Time frame: Baseline uo tp 5 years
Percentage of Participants by the Site of First Disease Progression
Time frame: Baseline up to 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.